China approves Innovent sNDA for hepatocellular carcinoma treatment
Discovered and developed by Lilly, Cyramza has been approved for the treatment of HCC patients with an alpha fetoprotein of ≥400 ng/mL and who have received treatment with
The partnership will particularly focus on identifying composite biomarkers, which integrate several biological entities into a single readout. This identification will help guide therapeutic decision making. Gastroesophageal cancer
Under the deal, both entities will focus on discovering and developing new therapeutics based on small interfering RNA (siRNA) technology. The partnership will identify new therapeutic targets, which are